Cancer epigenomics: implications of DNA methylation in personalized cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Genetic alterations in tumors can inform chemotherapy drug sensitivity.
• The low frequency of mutations limits the broad utility of pharmacogenomics.
• Epigenetic changes, specifically DNA methylation, are common in human cancers.

Purpose of the Study:

• To explore DNA methylation as a potential biomarker for predicting tumor response to chemotherapy.
• To highlight the limitations of current pharmacogenomic approaches.
• To emphasize the need for advanced molecular analysis in cancer research.

Main Methods:

• Review of existing literature on genetic alterations and DNA methylation in cancer.
• Identification of key genes (e.g., MGMT, hMLH1, WRN, FANCF, CHFR, p73) whose methylation status affects drug sensitivity.
• Discussion of the potential of DNA methylation as a predictive marker.

Main Results:

• DNA methylation of specific genes involved in DNA repair, genome integrity, and cell-cycle checkpoints influences chemotherapy sensitivity.
• Methylation patterns suggest potential as molecular markers for predicting tumor responsiveness.
• Current comprehensive studies are limited by the need for advanced genome-wide DNA methylation analysis.

Conclusions:

• DNA methylation represents a promising avenue for predicting chemotherapy response in cancer patients.
• Pharmacoepigenomics holds potential for personalized cancer treatment.
• Advancements in genome-wide DNA methylation analysis technologies are crucial for realizing the full potential of this field.